Abstract 1927: Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors
Urszula N. Wasko(Revolution Medicines (United States)), Kenneth P. Olive(Columbia University Irving Medical Center), Tanner C. Dalton(Columbia University Irving Medical Center), Marie Ménard(University of California, San Francisco), Matthew Holderfield(Revolution Medicines (United States)), Stephen A. Sastra(Columbia University Irving Medical Center), Elsa Quintana(Revolution Medicines (United States)), Scott W. Lowe(Memorial Sloan Kettering Cancer Center), Jacqueline A.M. Smith(Revolution Medicines (United States)), Julien Dilly(Massachusetts Institute of Technology), Sha Tian(Macau University of Science and Technology), Yingyun Wang(Revolution Medicines (United States)), David Wildes(Revolution Medicines (United States)), Robert H. Vonderheide(University of Pennsylvania), Andrea Califano(Columbia University Irving Medical Center), Ben Z. Stanger(Cancer Research Institute), Mallika Singh(Revolution Medicines (United States)), Margo Orlen(UPMC Hillman Cancer Center), Channing J. Der(University of North Carolina at Chapel Hill), Stephanie Chang, Lingyan Jiang(Hainan University), Cole Edwards(University of North Carolina at Chapel Hill), Álvaro Curiel‐García(Columbia University Irving Medical Center), Andrew J. Aguirre(Broad Institute), Carmine F. Palermo(Columbia University Irving Medical Center), Lorenzo Tomassoni(Columbia University Irving Medical Center), Jingjing Jiang(Revolution Medicines (United States)), Timour Baslan(University of Pennsylvania), Zhengping Wang(Shandong University), Clint A. Stalnecker(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Efficient tumour formation by single human melanoma cells
|Nature|2008|1.8k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal
|Immunity|1998|1.1k